215922-85-3

Basic information

• Product Name: trans-1-Boc-3-cyano-4-hydroxypyrrolidine
• Synonyms: trans-1-Boc-3-cyano-4-hydroxypyrrolidine;trans-tert-Butyl 3-cyano-4-hydroxypyrrolidine-1-carboxylate;tert-butyl trans-3-cyano-4-hydroxypyrrolidine-1-carboxylate
• CAS NO: 215922-85-3
• Molecular Formula: C10H16N2O3
• Molecular Weight: 212.24564
• Product Categories: pharmacetical
• Mol File: 215922-85-3.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 361.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.48±0.40(Predicted)
• CAS DataBase Reference: trans-1-Boc-3-cyano-4-hydroxypyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: trans-1-Boc-3-cyano-4-hydroxypyrrolidine(215922-85-3)
• EPA Substance Registry System: trans-1-Boc-3-cyano-4-hydroxypyrrolidine(215922-85-3)

Safety Data

• Hazardous Substances Data: 215922-85-3(Hazardous Substances Data)

Usage

General Description

Trans-1-Boc-3-cyano-4-hydroxypyrrolidine is a chemical compound that is commonly used in organic synthesis and medicinal chemistry. It is a derivative of pyrrolidine, containing a tert-butoxycarbonyl (Boc) protecting group at the first position, a cyano group at the third position, and a hydroxyl group at the fourth position of the pyrrolidine ring. trans-1-Boc-3-cyano-4-hydroxypyrrolidine is often employed as a building block for the synthesis of various pharmaceuticals, agrochemicals, and other fine chemicals. Its unique structure and reactivity make it a valuable intermediate in the production of complex organic molecules. The compound is known for its stability and versatility, making it an important tool for chemical research and drug discovery.

Upstream product

• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 913744-14-6 (S,S)-3-acetoxy-4-cyano-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 197143-33-2 tert-butyl 3-cyano-4-hydroxypyrrolidine-1-carboxylate 
• 108-05-4 vinyl acetate 
• 7677-24-9 trimethylsilyl cyanide 
• 114214-49-2 rac-tert-butyl (1R,5S)-6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 5804-85-3 diethylaluminium cyanide 
• 252574-02-0 (±)-trans-tert-butyl 3-bromo-4-hydroxypyrrolidine-1-carboxylate 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 266353-18-8 N-tert-butoxycarbonyl-2-(2-cyanoethyl)aminoacetic acid ethyl ester 
• 44981-94-4 N-cyanoethyl glycine ethyl ester 
• 175463-32-8 3-cyano-4-oxopyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 773826-73-6 tert-butyl 3-(aminomethyl)-4-hydroxypyrrolidine-1-carboxylate 
• 895241-95-9 (3S,4S)-3-cyano-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 895241-94-8 (R,R)-3-hydroxy-4-cyano-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 913744-14-6 (S,S)-3-acetoxy-4-cyano-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 175463-34-0 4-(tert-butoxycarbonyl)aminomethyl-1-(t-butoxycarbonyl)pyrrolidin-3-ol 

Relevant articles and documents

Preparation and application of imidazo aromatic ring compounds

The invention provides preparation and application of imidazo aromatic ring compounds, and particularly provides compounds as shown in the following formula I. The definition of each group is as shownin the specification. The compounds have TRK kinase inh

PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES

The present invention relates to pyrazolo [1,5 -a] [1,3,5 ]triazine and pyrazolo[1,5-a] pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazo lo [1,5-a][1,3,5 ]triazine and pyrazolo [1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Pyrazolo[1,5-A]pyrimidines as antiviral agents

The invention provides compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections. The compounds and compositions are useful for treating Pneumovirinae virus infection including Human respiratory syncytial virus infections.